189 related articles for article (PubMed ID: 21440449)
1. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Yenugonda VM; Deb TB; Grindrod SC; Dakshanamurthy S; Yang Y; Paige M; Brown ML
Bioorg Med Chem; 2011 Apr; 19(8):2714-25. PubMed ID: 21440449
[TBL] [Abstract][Full Text] [Related]
2. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
Węsierska-Gądek J; Hackl S; Zulehner N; Maurer M; Komina O
J Cell Biochem; 2011 Jan; 112(1):273-88. PubMed ID: 21080333
[TBL] [Abstract][Full Text] [Related]
3. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.
Knockaert M; Lenormand P; Gray N; Schultz P; Pouysségur J; Meijer L
Oncogene; 2002 Sep; 21(42):6413-24. PubMed ID: 12226745
[TBL] [Abstract][Full Text] [Related]
4. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
[TBL] [Abstract][Full Text] [Related]
5. Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src.
Hikita T; Oneyama C; Okada M
Genes Cells; 2010 Oct; 15(10):1051-62. PubMed ID: 20825494
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A; Schwartz GK
Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
[TBL] [Abstract][Full Text] [Related]
7. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule cyclin-dependent kinase modulators.
Senderowicz AM
Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
[TBL] [Abstract][Full Text] [Related]
9. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
Conroy A; Stockett DE; Walker D; Arkin MR; Hoch U; Fox JA; Hawtin RE
Cancer Chemother Pharmacol; 2009 Sep; 64(4):723-32. PubMed ID: 19169685
[TBL] [Abstract][Full Text] [Related]
10. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
11. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
Akin S; Babacan T; Sarici F; Altundag K
J BUON; 2014; 19(1):42-6. PubMed ID: 24659641
[TBL] [Abstract][Full Text] [Related]
12. Physalis angulata induced G2/M phase arrest in human breast cancer cells.
Hsieh WT; Huang KY; Lin HY; Chung JG
Food Chem Toxicol; 2006 Jul; 44(7):974-83. PubMed ID: 16427178
[TBL] [Abstract][Full Text] [Related]
13. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins.
Zi X; Feyes DK; Agarwal R
Clin Cancer Res; 1998 Apr; 4(4):1055-64. PubMed ID: 9563902
[TBL] [Abstract][Full Text] [Related]
14. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
15. Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity.
Simone M; Erba E; Damia G; Vikhanskaya F; Di Francesco AM; Riccardi R; Bailly C; Cuevas C; Fernandez Sousa-Faro JM; D'Incalci M
Eur J Cancer; 2005 Oct; 41(15):2366-77. PubMed ID: 16181779
[TBL] [Abstract][Full Text] [Related]
16. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
[TBL] [Abstract][Full Text] [Related]
17. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.
Liu Y; Lu C; Shen Q; Munoz-Medellin D; Kim H; Brown PH
Oncogene; 2004 Oct; 23(50):8238-46. PubMed ID: 15378019
[TBL] [Abstract][Full Text] [Related]
18. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
Węsierska-Gądek J; Kramer MP
Expert Opin Investig Drugs; 2011 Dec; 20(12):1611-28. PubMed ID: 22017180
[TBL] [Abstract][Full Text] [Related]
19. VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells.
Ringer L; Sirajuddin P; Yenugonda VM; Ghosh A; Divito K; Trabosh V; Patel Y; Brophy A; Grindrod S; Lisanti MP; Rosenthal D; Brown ML; Avantaggiati ML; Rodriguez O; Albanese C
Cancer Biol Ther; 2010 Aug; 10(4):320-5. PubMed ID: 20574155
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
Balakrishnan A; Vyas A; Deshpande K; Vyas D
World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
